Literature DB >> 26152921

INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency.

Thanh-Trang T Vo1, David A Fruman2.   

Abstract

Enzymes (PI3K and PTEN) controlling cellular levels of 3-phosphorylated phosphoinositides are known as important drivers or suppressors of tumorigenesis in various cancers. In this issue of Cancer Discovery, Kofuji and colleagues and Chew and colleagues identify the lipid phosphatase INPP4B as a context-specific tumor suppressor that controls phosphoinositide levels and AKT2 activation in PTEN-deficient cells. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26152921      PMCID： PMC4499858          DOI： 10.1158/2159-8290.CD-15-0609

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  10 in total

1.  Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration.

Authors:  Andrea Palamidessi; Emanuela Frittoli; Massimiliano Garré; Mario Faretta; Marina Mione; Ilaria Testa; Alberto Diaspro; Letizia Lanzetti; Giorgio Scita; Pier Paolo Di Fiore
Journal:  Cell       Date:  2008-07-11       Impact factor: 41.582

2.  Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.

Authors:  Clare G Fedele; Lisa M Ooms; Miriel Ho; Jessica Vieusseux; Sandra A O'Toole; Ewan K Millar; Elena Lopez-Knowles; Absorn Sriratana; Rajendra Gurung; Laura Baglietto; Graham G Giles; Charles G Bailey; John E J Rasko; Benjamin J Shields; John T Price; Philip W Majerus; Robert L Sutherland; Tony Tiganis; Catriona A McLean; Christina A Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-02       Impact factor: 11.205

3.  SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.

Authors:  Jessica A Gasser; Hiroyuki Inuzuka; Alan W Lau; Wenyi Wei; Rameen Beroukhim; Alex Toker
Journal:  Mol Cell       Date:  2014-10-30       Impact factor: 17.970

Review 4.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

5.  INPP4B Is a PtdIns(3,4,5)P3 Phosphatase That Can Act as a Tumor Suppressor.

Authors:  Satoshi Kofuji; Hirotaka Kimura; Hiroki Nakanishi; Hiroshi Nanjo; Shunsuke Takasuga; Hui Liu; Satoshi Eguchi; Ryotaro Nakamura; Reietsu Itoh; Noriko Ueno; Ken Asanuma; Mingguo Huang; Atsushi Koizumi; Tomonori Habuchi; Masakazu Yamazaki; Akira Suzuki; Junko Sasaki; Takehiko Sasaki
Journal:  Cancer Discov       Date:  2015-04-16       Impact factor: 39.397

6.  In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.

Authors:  Chen Li Chew; Andrea Lunardi; Federico Gulluni; Daniel T Ruan; Ming Chen; Leonardo Salmena; Michiya Nishino; Antonella Papa; Christopher Ng; Jacqueline Fung; John G Clohessy; Junko Sasaki; Takehiko Sasaki; Roderick T Bronson; Emilio Hirsch; Pier Paolo Pandolfi
Journal:  Cancer Discov       Date:  2015-04-16       Impact factor: 39.397

Review 7.  Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.

Authors:  Qingshan Yang; Prexy Modi; Terry Newcomb; Christophe Quéva; Varsha Gandhi
Journal:  Clin Cancer Res       Date:  2015-02-10       Impact factor: 12.531

8.  Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.

Authors:  Christina Gewinner; Zhigang C Wang; Andrea Richardson; Julie Teruya-Feldstein; Dariush Etemadmoghadam; David Bowtell; Jordi Barretina; William M Lin; Lucia Rameh; Leonardo Salmena; Pier Paolo Pandolfi; Lewis C Cantley
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

9.  INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival.

Authors:  Natalie K Rynkiewicz; Clare G Fedele; Karen Chiam; Ruta Gupta; James G Kench; Lisa M Ooms; Catriona A McLean; Graham G Giles; Lisa G Horvath; Christina A Mitchell
Journal:  Prostate       Date:  2014-10-04       Impact factor: 4.104

10.  Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.

Authors:  Annika Stjernström; Christina Karlsson; Oswaldo J Fernandez; Peter Söderkvist; Mats G Karlsson; Lena K Thunell
Journal:  Cancer Med       Date:  2014-02-05       Impact factor: 4.452
  10 in total
  10 in total

Review 1.  Proteomics and its applications in breast cancer.

Authors:  Anca-Narcisa Neagu; Danielle Whitham; Emma Buonanno; Avalon Jenkins; Teodora Alexa-Stratulat; Bogdan Ionel Tamba; Costel C Darie
Journal:  Am J Cancer Res       Date:  2021-09-15       Impact factor: 5.942

2.  A model of twenty-three metabolic-related genes predicting overall survival for lung adenocarcinoma.

Authors:  Zhenyu Zhao; Boxue He; Qidong Cai; Pengfei Zhang; Xiong Peng; Yuqian Zhang; Hui Xie; Xiang Wang
Journal:  PeerJ       Date:  2020-09-24       Impact factor: 2.984

3.  Investigating the duality of Inpp4b function in the cellular transformation of mouse fibroblasts.

Authors:  Emily Marie Mangialardi; Keyue Chen; Brittany Salmon; Jean Vacher; Leonardo Salmena
Journal:  Oncotarget       Date:  2019-10-29

4.  miR-1290 Contributes to Colorectal Cancer Cell Proliferation by Targeting INPP4B.

Authors:  Qingzhu Ma; Yan Wang; Hualing Zhang; Fengqiang Wang
Journal:  Oncol Res       Date:  2017-09-15       Impact factor: 5.574

Review 5.  An Insight into miR-1290: An Oncogenic miRNA with Diagnostic Potential.

Authors:  Małgorzata Guz; Witold Jeleniewicz; Marek Cybulski
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

Review 6.  Targeting SHIP1 and SHIP2 in Cancer.

Authors:  Chiara Pedicone; Shea T Meyer; John D Chisholm; William G Kerr
Journal:  Cancers (Basel)       Date:  2021-02-20       Impact factor: 6.639

7.  INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.

Authors:  Hongjun Jin; Liyuan Yang; Lu Wang; Zailin Yang; Qian Zhan; Yao Tao; Qin Zou; Yuting Tang; Jingrong Xian; Shuaishuai Zhang; Yipei Jing; Ling Zhang
Journal:  J Exp Clin Cancer Res       Date:  2018-01-17

8.  PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K.

Authors:  Mouhannad Malek; Anna Kielkowska; Tamara Chessa; Karen E Anderson; David Barneda; Pınar Pir; Hiroki Nakanishi; Satoshi Eguchi; Atsushi Koizumi; Junko Sasaki; Véronique Juvin; Vladimir Y Kiselev; Izabella Niewczas; Alexander Gray; Alexandre Valayer; Dominik Spensberger; Marine Imbert; Sergio Felisbino; Tomonori Habuchi; Soren Beinke; Sabina Cosulich; Nicolas Le Novère; Takehiko Sasaki; Jonathan Clark; Phillip T Hawkins; Len R Stephens
Journal:  Mol Cell       Date:  2017-10-19       Impact factor: 17.970

Review 9.  PI(3,4)P2 Signaling in Cancer and Metabolism.

Authors:  Luca Gozzelino; Maria Chiara De Santis; Federico Gulluni; Emilio Hirsch; Miriam Martini
Journal:  Front Oncol       Date:  2020-03-31       Impact factor: 6.244

10.  Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review.

Authors:  Hong-Shuai Li; Li-Li Yang; Ming-Yi Zhang; Ke Cheng; Ye Chen; Ji-Yan Liu
Journal:  Front Oncol       Date:  2020-10-26       Impact factor: 6.244
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.